With shares of Rockwell Medical (NASDAQ:RMTI) down 50% YTD, and with short interest down to 8% of float, I believe that the short thesis has finally lost its footing. Rockwell has bounced somewhat from its low of $3.16 on March 20th, but is well off the 52-week high of $10.70 in June of 2012. This discounted price offers investors a low entry point going into the release of Phase III data expected next month.
Rockwell is a biopharmaceutical company focusing on products for patients on dialysis, especially those patients with end-stage renal disease (ESRD), chronic kidney disease, and iron deficiency anemia. The company already has a $50 million per year business selling dialysis products, and currently has an...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|